RxDoctor Payments Data

Carrie Finke, MD

Internal Medicine · West Plains, MONPI 1134218605

Payments from drug & device makers

$923in general payments, 2019–2025

Across 50 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$196
  • Novo Nordisk$165
  • Dexcom, Inc.$115
  • AstraZeneca$112
  • Pfizer$84
  • Boehringer Ingelheim$73
  • plus $179 from 5 others

What the payments were for

  • Food & beverage$85893%
  • Education$303%
  • Other$364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$923 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$633
Medicare patients
36
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide204$206,494
TrulicityDulaglutide80$108,121
JardianceEmpagliflozin95$103,884
Tresiba Flextouch U-100Insulin Degludec123$72,269
EliquisApixaban93$66,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$40,432
XareltoRivaroxaban31$29,625
RexultiBrexpiprazole18$27,969
Tresiba Flextouch U-200Insulin Degludec15$15,836
MounjaroTirzepatide14$13,862
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$11,956
Nurtec OdtRimegepant Sulfate12$11,078
RybelsusSemaglutide11$9,928
Bydureon BciseExenatide Microspheres11$8,789
SymbicortBudesonide/Formoterol Fumarate29$8,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$165$216,422215 claims
Lilly USA, LLCTrulicity, Mounjaro$67$121,98494 claims
Boehringer IngelheimJardiance$73$103,88495 claims
PfizerEliquis, Nurtec Odt, Premarin$84$79,979117 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$28$50,44982 claims
AstraZenecaSymbicort, Breztri Aerosphere$112$15,14841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in West Plains

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →